CCHIO 2024 | Prof. Winckworth-Prejsnar: Advancing Evidence-Based Cancer Treatment through Global Collaboration

CCHIO 2024 | Prof. Winckworth-Prejsnar: Advancing Evidence-Based Cancer Treatment through Global Collaboration

2024.12.06
From November 14–17, the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) and the Asian Oncology Society (AOS 2024) convened in Xi'an. Jointly organized by the Chinese Anti-Cancer Association (CACA), the Union for International Cancer Control (UICC), and the National Comprehensive Cancer Network (NCCN®), the event featured a specialized session on "International Collaboration: CACA-UICC & CACA-NCCN."
CCHIO 2024 | Prof. Naoufal Louati: Unlocking the Potential of TCM in Cancer Care and Strengthening China-Morocco Collaboration

CCHIO 2024 | Prof. Naoufal Louati: Unlocking the Potential of TCM in Cancer Care and Strengthening China-Morocco Collaboration

2024.12.06
The 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) recently convened in Xi'an, bringing together global experts and scholars to discuss the latest advancements in cancer treatment and foster international cooperation. Among the distinguished participants was Prof. Naoufal Louati, President of the Moroccan Institute of Traditional Chinese Medicine, who delivered a keynote presentation titled "Global Progress on Holistic Cancer Care." Following his address, Oncology Frontier interviewed Prof. Louati to discuss his experience at the conference, his insights into the role of Traditional Chinese Medicine (TCM) in cancer treatment, and the promising prospects for China-Morocco collaboration in cancer research and prevention.
The academic grand event on urological tumors is coming, and the live-streaming feast is about to begin!

The academic grand event on urological tumors is coming, and the live-streaming feast is about to begin!

2024.12.06
Dear colleagues in the medical field, the 14th Shanghai Genitourinary Oncology Academic Conference & Annual Meeting of Chinese Anti-Cancer Association-Genital Oncology Committee (CACA-GO) will be held grandly from December 6th to 8th ! This is a "highlight moment" in the field of urology. It focuses on the cutting-edge progress and innovative achievements. Many top-notch experts and scholars from both home and abroad will gather together to conduct in-depth discussions, covering multiple aspects such as surgical innovation, basic research, and translational medicine, presenting a veritable "feast" of academic knowledge.
CTI 2024 | ACTO Chairman Dr. Akihiro Shimosaka: Exosomes Empower Innovative Breakthroughs in Immune Cell Therapy

CTI 2024 | ACTO Chairman Dr. Akihiro Shimosaka: Exosomes Empower Innovative Breakthroughs in Immune Cell Therapy

2024.12.05
From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. "Hematology Frontier" specially invited the conference chair and the chairman of the Asian Cellular Therapy Organization (ACTO), Dr. Akihiro Shimosaka, to share his profound insights on immune cell therapy, regenerative medicine, gene therapy, and the application of exosomes.
CTI 2024 | Dr. Leo Luznik Shares Exploration and Prospects of Bone Marrow Infiltrating T Cells in the Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

CTI 2024 | Dr. Leo Luznik Shares Exploration and Prospects of Bone Marrow Infiltrating T Cells in the Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

2024.12.05
From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During the conference, "Hematology Frontier" specially invited Dr. Leo Luznik from Baylor College of Medicine,USA to share the latest progress of Bone Marrow Infiltrating T Cells (MITs) in the treatment of relapse after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). He revealed the potential and challenges of MITs in treating relapse after HSCT and looked forward to the future development direction of the field.
CTI 2024 | Dr. Marion Subklewe Reveals How AdCAR-T Cells Dualistically Enhance the Safety and Precision of AML Treatment

CTI 2024 | Dr. Marion Subklewe Reveals How AdCAR-T Cells Dualistically Enhance the Safety and Precision of AML Treatment

2024.12.05
From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During the conference, "Hematology Frontier" specially invited Dr. Marion Subklewe from the LMU University Hospital , Germany, to share with us the principles, advantages of AdCAR-T cell technology, and the future optimization direction of AML treatment.
CTI 2024 | IACH Chairman Dr. Mohamad Mohty: Updates on the Latest Treatment Advances in GVHD

CTI 2024 | IACH Chairman Dr. Mohamad Mohty: Updates on the Latest Treatment Advances in GVHD

2024.12.05
From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During this conference, "Hematology Frontier" specially invited the conference chair and the chairman of the International Academy for Clinical Hematology (IACH), Dr. Mohamad Mohty from Sorbonne University , France, to share his insights on the latest treatment advances in Graft-Versus-Host Disease (GVHD), aiming to provide valuable insights for clinicians and researchers and to explore the future direction of GVHD treatment.